<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420784</url>
  </required_header>
  <id_info>
    <org_study_id>VX06-950-106</org_study_id>
    <nct_id>NCT00420784</nct_id>
  </id_info>
  <brief_title>A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)</brief_title>
  <official_title>A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys速), and Ribavirin (Copegus速) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an
      investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a
      (Peg-IFN-alfa-2a, Pegasys速), and Ribavirin (RBV, Copegus速) in people with genotype 1
      hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment
      of interferon therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</measure>
    <time_frame>24 weeks after the completion of study drug dosing (up to Week 72)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</measure>
    <time_frame>Completion of study drug dosing (up to Week 48)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Undetectable Plasma HCV RNA</measure>
    <time_frame>Up to Week 96 (24 weeks after last dose of study drug for PBO group; 48 weeks after last dose of study drug for telaprevir groups)</time_frame>
    <description>Percentage of subjects with undetectable HCV RNA at 24 weeks after last dose of study drug for treatment group &quot;PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week&quot; and at 48 weeks after last dose of study drug for treatment groups &quot;Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week&quot;, &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week&quot; and &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week&quot; were presented. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 2 weeks after last dose of study drug (up to Week 50)</time_frame>
    <description>AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. &quot;Study drug&quot; includes all investigational agents (including placebo, if applicable) administered during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Viral Relapse</measure>
    <time_frame>After last dose of study drug up to 24 week antiviral follow-up (up to Week 72)</time_frame>
    <description>Viral relapse was defined as having detectable HCV RNA during antiviral follow-up. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 24</time_frame>
    <description>Only subjects who received telaprevir were to be analyzed for this outcome. Maximum, minimum and average plasma concentrations observed during assessment period were reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">465</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>tablet</description>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</arm_group_label>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</arm_group_label>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</arm_group_label>
    <other_name>VX-950</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>tablet</description>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</arm_group_label>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</arm_group_label>
    <arm_group_label>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon Alfa 2a</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</arm_group_label>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</arm_group_label>
    <arm_group_label>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</arm_group_label>
    <arm_group_label>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <other_name>Peg-IFN-alfa-2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 18 and 70 years old

          -  Detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal
             to (&gt;=) 10,000 international units per milliliter (IU/mL)

          -  Must have chronic hepatitis C (genotype 1) and have already received at least one
             prior course of pegylated interferon alfa 2a with ribavirin

          -  Cannot also be infected with Human Immunodeficiency Virus or hepatitis B

          -  Must be judged to be in general good health and able to receive Pegasys速 and Copegus速

          -  No drug or alcohol abuse in the last year

          -  Must agree to use two effective methods of birth control during the study and for 6
             months after you stop taking study medication. One of the methods needs to be a
             'barrier' method (condom or diaphragm)

          -  If you are a woman, you cannot be in this study if you are pregnant or nursing

        Exclusion Criteria:

          -  Participation in any clinical trial of a HCV protease inhibitor of any duration

          -  Prior response to therapy and failure to achieve SVR which was due to treatment
             non-compliance

          -  Any other cause of significant liver disease in addition to hepatitis C; this may
             include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis,
             autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis,
             or primary biliary cirrhosis

          -  Diagnosed or suspected hepatocellular carcinoma

          -  History of or current evidence of decompensated liver disease

          -  Participation in any clinical trial of an investigational drug within 90 days before
             drug administration or participation in more than 2 drug studies in the last 12 months
             (exclusive of the current study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Vertex Pharmaceuticals Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Gastroenterology Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hepatology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hepatitis Center at Bach &amp; Godofsky</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virology Treatment Center, Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Isreal Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Internal Medicine Associates, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Gastroenterology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology Group</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute at Methodist Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Medical Clinic - Health Science Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Hepatitis Program</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Frankfurt, Department of Internal Medicine</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santurce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>June 22, 2011</results_first_submitted>
  <results_first_submitted_qc>June 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2011</results_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 465 subjects were enrolled, of which 12 subjects discontinued the study prior to study drug administration. A total of 453 subjects started treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
          <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
          <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
          <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
          <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="111"/>
                <participants group_id="P4" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Virologic Stopping Rule</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
          <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
          <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
          <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
          <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="114"/>
            <count group_id="B5" value="453"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="7.8"/>
                    <measurement group_id="B2" value="52.0" spread="5.5"/>
                    <measurement group_id="B3" value="51.9" spread="7.1"/>
                    <measurement group_id="B4" value="49.8" spread="7.2"/>
                    <measurement group_id="B5" value="50.8" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
        <time_frame>24 weeks after the completion of study drug dosing (up to Week 72)</time_frame>
        <population>Full Analysis Set = subjects who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
            <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
          <population>Full Analysis Set = subjects who received at least 1 dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="53.1"/>
                    <measurement group_id="O3" value="24.3"/>
                    <measurement group_id="O4" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.14</ci_lower_limit>
            <ci_upper_limit>16.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.72</ci_lower_limit>
            <ci_upper_limit>19.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>4.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
        <time_frame>Completion of study drug dosing (up to Week 48)</time_frame>
        <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
            <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
          <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Undetectable Plasma HCV RNA</title>
        <description>Percentage of subjects with undetectable HCV RNA at 24 weeks after last dose of study drug for treatment group &quot;PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week&quot; and at 48 weeks after last dose of study drug for treatment groups &quot;Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week&quot;, &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week&quot; and &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week&quot; were presented. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
        <time_frame>Up to Week 96 (24 weeks after last dose of study drug for PBO group; 48 weeks after last dose of study drug for telaprevir groups)</time_frame>
        <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
            <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Undetectable Plasma HCV RNA</title>
          <description>Percentage of subjects with undetectable HCV RNA at 24 weeks after last dose of study drug for treatment group &quot;PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week&quot; and at 48 weeks after last dose of study drug for treatment groups &quot;Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week&quot;, &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week&quot; and &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week&quot; were presented. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
          <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="44.2"/>
                    <measurement group_id="O3" value="22.5"/>
                    <measurement group_id="O4" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.41</ci_lower_limit>
            <ci_upper_limit>12.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.91</ci_lower_limit>
            <ci_upper_limit>11.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>4.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. &quot;Study drug&quot; includes all investigational agents (including placebo, if applicable) administered during the course of the study.</description>
        <time_frame>Baseline up to 2 weeks after last dose of study drug (up to Week 50)</time_frame>
        <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
            <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. &quot;Study drug&quot; includes all investigational agents (including placebo, if applicable) administered during the course of the study.</description>
          <population>Full Analysis Set = subjects who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Viral Relapse</title>
        <description>Viral relapse was defined as having detectable HCV RNA during antiviral follow-up. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
        <time_frame>After last dose of study drug up to 24 week antiviral follow-up (up to Week 72)</time_frame>
        <population>Analysis population included subjects who completed their assigned study drug treatment and had undetectable HCV RNA at the completion of treatment (up to Week 48).</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
            <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
            <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Viral Relapse</title>
          <description>Viral relapse was defined as having detectable HCV RNA during antiviral follow-up. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).</description>
          <population>Analysis population included subjects who completed their assigned study drug treatment and had undetectable HCV RNA at the completion of treatment (up to Week 48).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</title>
        <description>Only subjects who received telaprevir were to be analyzed for this outcome. Maximum, minimum and average plasma concentrations observed during assessment period were reported.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 24</time_frame>
        <population>Pharmacokinetic population included all subjects who provided pharmacokinetic assessments and had evaluable and interpretable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir</title>
            <description>All subjects who received single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in &quot;Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week&quot; reporting group and for 24 weeks in &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week&quot; and &quot;Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week&quot; reporting groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</title>
          <description>Only subjects who received telaprevir were to be analyzed for this outcome. Maximum, minimum and average plasma concentrations observed during assessment period were reported.</description>
          <population>Pharmacokinetic population included all subjects who provided pharmacokinetic assessments and had evaluable and interpretable data.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2755" spread="811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2335" spread="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2610" spread="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 2 weeks after last dose of study drug (up to Week 50)</time_frame>
      <desc>In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables.</desc>
      <group_list>
        <group group_id="E1">
          <title>Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week</title>
          <description>Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week</title>
          <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week</title>
          <description>Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
          <description>Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Infected insect bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell unclassifiable lymphoma low grade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="111" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Chodakewitz, M.D.</name_or_title>
      <organization>Vertex Pharmaceuticals Incorporated</organization>
      <phone>617-341-6777</phone>
      <email>Jeff_Chodakewitz@vrtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

